Curriculum · Gynecology / Women's Health / Infertility / Perinatal Care / Birth Spacing
Chorionic villus sampling
What it is
Chorionic villous sampling, CVS, is one of the invasive procedures of pregnancy. A first trimester scan is indicated during a diagnostic or therapeutic procedure such as chorionic villous sampling, so the scan is part of the procedure and not only a step before it. It is a biopsy of tissue from the villous area of the chorion, derived from the trophoblast, taken transcervically or transabdominally at 10-12 weeks, against amniocentesis, which is done after 15 weeks and draws amniotic fluid whose amniocytes are fetal cells, mostly from fetal skin, grown in culture for chromosomal analysis and DNA studies. Both are the invasive arm of prenatal diagnosis, the detection of abnormalities in the fetus before birth. The non-invasive arm is ultrasonography for anatomical details and nuchal translucency, first and second trimester maternal serum screening, and isolation of fetal cells from the maternal circulation, which can be done from the 10th week and increases with advancing gestational age. Prenatal diagnosis gives couples at risk a range of informed choice, provides reassurance and removes anxiety in high risk groups, allows the option of appropriate psychological, pregnancy, delivery and postnatal management, and can enable prenatal treatment of the fetus.
How it is diagnosed
For trisomy 21, Down syndrome, the diagnostic investigation in pregnancy is amniocentesis or CVS. The mode of inheritance it shows is non-disjunction, Robertsonian translocation usually onto 14, or mosaicism. Those who benefit from prenatal diagnosis are older women over 35, at increased risk of chromosome disorders; a mother whose disease is associated with an increased risk of birth defects; a known teratogen exposure during pregnancy; a family history of sex linked or autosomal traits; a parent known to carry a balanced structural abnormality such as a translocation or an inversion; and a history of recurrent miscarriages. For chorionic villus sampling the result is available at an early stage of pregnancy and chromosome analysis is successful in more than 99% of cases.
The invasive test is not the first step. Where a woman at 10 weeks of gestation asks to be referred for an amniocentesis because a friend has just delivered a newborn with trisomy 21 syndrome, the most appropriate next step is to discuss the options for prenatal screening with her: not to refer her for an amniocentesis, not to refer her for chorionic-villus sampling, not to advise that screening is unnecessary because the risk is low, and not to tell her that a detailed ultrasonography at 19 weeks will be adequate screening.
The same holds where the question is the fetal RhD status. In an RhD negative woman at 10 weeks of gestation whose partner is RhD positive and, having one RhD positive and one RhD negative child, can be assumed heterozygote for the RhD antigen, so that each of their future children has a 50% chance of being RhD-antigen positive, the most appropriate next step is to offer cell-free DNA screening to determine the fetal RHD status. Cell-free DNA testing is very accurate, with a sensitivity above 99% and very few false-negatives, and it avoids the risks of invasive procedures such as amniocentesis and chorionic villus sampling. Determining the fetal RhD genotype allows targeted prophylaxis, where the fetus is RhD positive, as early as 10 weeks during the pregnancy, and it lets the woman avoid receiving RhD immune globulin if her fetus is RhD negative. What it is chosen over is amniocentesis at 16 weeks of gestation, chorionic villous sampling at 13 weeks of gestation, determining the partner's RhD zygosity, and advice to administer Rh immune globulin at 28 weeks of gestation.